Tim has worked in the pharmaceutical and biotech sectors since 1990 with experience in both Big Pharma and both public and privately-held SMEs. Most recently, from August 2018 to September 2021 he was at AIM-listed Shield Therapeutics plc (L.STX), a company focused on commercialising its innovative iron deficiency therapy, where he was initially CFO and then latterly CEO and a director from April 2020. From 2012 to 2017 Tim was CFO and a director of Oxford BioMedica PLC (L.OXB), a world-leading cell and gene therapy company, when the management team grew the Group’s market capitalisation from £30 million to £330 million and laid the foundations for the business it is today. Prior to Oxford BioMedica, from 2007 to 2011 Tim was CFO of Archimedes Pharma, a private-equity backed specialty pharma company, and before that from 1990 to 2007 he was in a variety of increasingly senior roles at AstraZeneca, including Group Financial Controller from 2002 to 2006.
Tim is also a non-executive director at Cellesce Limited, which has invented and patented a unique bioprocess for the expansion of human-derived, normal and cancer organoids for a multitude of applications including drug discovery and organ-on-a-chip applications. Previously Tim was also a director of the UK’s BioIndustry Association from 2013 to 2017.